Report cover image

Immuno-Oncology (IO) - Thematic Intelligence

Publisher GlobalData
Published May 12, 2023
Length 169 Pages
SKU # GBDT17983347

Description

Immuno-Oncology (IO) - Thematic Intelligence


Summary

This report includes coverage of immuno-oncology overview, trends, value chain, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field.

The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation to remain the most valuable IO sector. 2022–23 has seen some IO success, but no major IO breakthrough has happened. Personalized treatment using biomarkers, therapeutic options for checkpoint refractory patients, and the high cost of therapy remain as unmet needs.

Key Highlights

Forecast includes 8 countries
Forecast covers 2022-2028
Seven markets are extrapolated, obtaining a 15-market value for all GBM therapeutics

Scope
  • This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell & gene therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.
Reasons to Buy

OBTAIN IMMUNO-ONCOLOGY MARKET ASSESSMENT AND FORECAST ACROSS MULTIPLE REGIONS

GAIN INSIGHT INTO PROMISING EARLY STAGE APPROACHES

Our indication specific forecast models answer questions such as -
  • What is the target patient pool for cell & gene therapies in each cancer indication?
  • Which patient groups are more likely to receive these therapies?
  • What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
  • What is the anticipated breakdown between autologous and allogeneic cell therapies?
  • When will cell & gene therapies launch in each market?
  • What is the total market value projected for the forecast end, in 2031?

Table of Contents

169 Pages
  • Related Reports
  • Executive Summary
    • What Is IO?
    • What Is Immuno-oncology?
    • What Is Immuno-oncology According to Regulators
    • Most Important Milestones of Immuno-oncology Development Globally
    • Key Twitter Chat
    • Industry Trends - Bispecific Antibodies
    • Industry Trends - Cancer Vaccines
    • Industry Trends - Cell Therapies
    • Industry Trends - Checkpoint Modulators
    • Industry Trends - Cytokines
    • Industry Trends - Oncolytic Viruses
    • Regulatory Trends
    • Immuno-oncology Value Chain
    • Bispecific Antibodies
    • Bispecific Antibodies - KOL Perspective
    • Cancer Vaccines
    • Cancer Vaccines - KOL Perspective
    • Cell Therapies
    • Cell Therapies - KOL Perspective
    • Checkpoint Modulators
    • Checkpoint Modulators - KOL Perspective
    • Next-Generation Cytokines
    • Cytokines - KOL Perspective
    • Oncolytic Viruses
    • Oncolytic Viruses - KOL Perspective
    • Immuno-oncology in Clinical Trials
    • In the Last Five Years, There Has Been an Explosion in the Number of IO Agents Receiving Approval
    • Total Market Size for IO Agents
    • 10 Highest-Grossing IO Treatments in 2022
    • Leading Checkpoint Modulators in the 8MM
    • Checkpoint Modulator Treatments - KOL Perspective
    • Leading BiTEs in the 8MM
    • BiTEs - KOL Perspective
    • Leading Cancer Vaccines and Oncolytic Viruses in the 8MM
    • Cancer Vaccine or Oncolytic Virus Treatments - KOL Perspective
    • Leading Cell Therapies in the 8MM
    • Cell Therapy Treatments - KOL Perspective
    • IO Pipeline Products in the 8MM
    • Future Outlook of IO Agents, According to High-Prescribing Physicians
    • Consensus Forecast Sales for the Top Three Pipeline Candidates per IO Class
    • The Forecast Highest-Grossing Bispecific Antibody Products
    • Bispecific Antibody Treatments - KOL Perspective
    • The Forecast Highest-Grossing Vaccine Products
    • Cancer Vaccine Treatments - KOL Perspective
    • The Forecast Highest-Grossing Cell Therapy Products
    • Cell Therapy Treatments - KOL Perspective
    • The Forecast Highest-Grossing Checkpoint Modulator Products
    • Checkpoint Modulator Treatments - KOL Perspective
    • The Forecast Highest-Grossing Cytokine Products
    • Cytokines - KOL Perspective
    • The Forecast Highest-Grossing Oncolytic Virus Products
    • Oncolytic Virus Treatments - KOL Perspective
    • Market Analysis and Forecast of the Six Classes of IO Agents
    • Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space
    • Latest Strategic Partnership Deals in the IO Space
    • Top 10 Mergers and Acquisitions that Include IO Assets: 2018-23
    • Latest Mergers and Acquisitions that Include IO Assets
    • IO in Clinical Trials
    • Clinical Trials
    • Endpoints in IO Clinical Trials - KOL Perspective
    • Challenges in IO Clinical Trials - KOL Perspective
    • Regulatory and Market Access - US
    • Key Market Access and Regulatory Concepts - US
    • Market Access - US Payer & KOL Perspective
    • Regulatory and Market Access - EU
    • Key Market Access and Regulatory Concepts - Europe
    • Market Access - EU Payer & KOL Perspective
    • Regulatory and Market Access - Japan
    • Key Market Access and Regulatory Concepts - Japan
    • Market Access - Japan KOL Perspective
    • Regulatory and Market Access - China
    • Key Market Access and Regulatory Concepts - China
    • Market Access - China KOL Perspective
    • Early Access Schemes
    • Barriers to Access According to High Prescribers
    • Bispecific Antibodies
    • Bispecific Antibodies - Additional KOL Perspective
    • Cancer Vaccines
    • Cancer Vaccines - Additional KOL Perspective
    • Cell Therapies
    • Cell Therapies - Additional KOL Perspective
    • Checkpoint Modulators
    • Checkpoint Modulators - Additional KOL Perspective
    • Cytokines
    • Cytokines - Additional KOL Perspective
    • Oncolytic Viruses
    • Oncolytic Viruses - Additional KOL Perspective
    • Clinical Unmet Needs in IO - Gap Analysis
    • Commercial Unmet Needs in Immuno-oncology - Gap Analysis
    • Unmet Needs - KOL Perspective
    • Unmet Needs According to High Prescribers
    • R&D Strategies
    • Opportunities for the Industry - Modern Approaches & Collaboration
    • Closing Remarks - In Their Words
    • Drug Development Scorecard - IO
    • Current Major Players - Novartis
    • Current Major Players - Merck & Co.
    • Current Major Players - Gilead Sciences
    • Current Major Players - Roche
    • Current Major Players - BMS
    • Current Major Players - AstraZeneca
    • Current Major Players - Sanofi
    • Current Major Players - Amgen
    • Current Major Players - Dendreon Pharmaceuticals
    • Current Major Players - Legend Biotech
    • Current Major Players - Johnson & Johnson
    • Current Major Players - Daiichi-Sankyo
    • Current Major Players - Kite
    • Current Major Players - Regeneron
    • Future Players Based on Pipeline Strength - Genmab
    • Future Players Based on Pipeline Strength - Iovance Therapeutics
    • Future Players Based on Pipeline Strength - Replimune
    • Future Players Based on Pipeline Strength - VBI Vaccines
    • Future Players Based on Pipeline Strength - Jounce Therapeutics (Acquired by Concentra Biosciences)
    • Future Players Based on Pipeline Strength - OncoSec
    • Future Players Based on Pipeline Strength - AbbVie
    • Future Players Based on Pipeline Strength - BioNTech
    • Future Players Based on Pipeline Strength - Greenwich LifeSciences
    • Future Players Based on Pipeline Strength - CRISPR Therapeutics
    • Future Players Based on Pipeline Strength - Allogene Therapeutics
    • Future Players Based on Pipeline Strength - Xilio Therapeutics
    • Future Players Based on Pipeline Strength - Candel Therapeutics
    • Sources
    • Primary Research
    • Key Themes Impacting the Pharmaceutical Industry
    • Our Thematic Research Methodology
    • About the Authors
    • Contact Us - A Global Network of Offices

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us